



EMERGENT®

We deliver peace of mind in an uncertain world

FACT SHEET

OCTOBER 2023

12

Marketed Products

Molecule-to-Market
BIOSERVICES

Development Services

Drug Substance

Drug Product

Packaging

1.12B

2022 Total Revenue

1,900

Employees



At Emergent, our mission is to **protect and enhance life.**

We develop, manufacture, and deliver protections against public health threats through a pipeline of innovative vaccines and therapeutics. For nearly 25 years, we've been at work defending people from things we hope will never happen—so that we're prepared, just in case they ever do. We do what we do because we see the opportunity to create a better, more secure world. One where preparedness empowers protection from the threats we face. And peace of mind prevails.



PRODUCT PORTFOLIO

GOVERNMENT/MEDICAL COUNTERMEASURES

BioThrax®

[Anthrax Vaccine
Absorbed]

CYFENDUS™

[Anthrax Vaccine Absorbed,
Adjuvanted]

Anthrasil®

[Anthrax Immune Globulin
Intravenous (Human)]

Raxibacumab Injection

A fully human monoclonal antibody

ACAM2000®

[Smallpox (Vaccinia)
Vaccine, Live]

VIGIV CNJ-016

[Vaccinia Immune Globulin
Intravenous (Human)]

BAT®

[Botulism Antitoxin
Heptavalent (A, B, C, D,
E, F, G) - (Equine)]

Ebanga™

(ansuvimab-zykl)

RSDL®

[Reactive Skin
Decontamination Lotion Kit]

TEMBEXA®

(brincidofovir)

Trobigard®¹

(Atropine sulfate/obidoxime
chloride auto-injector)

COMMERCIAL

NARCAN® Nasal Spray

(Naloxone HCl)



DEVELOPMENT AND MANUFACTURING EXPERTISE

EMERGENT BIOSERVICES

Molecule-to-market services across entire drug development life cycle from clinical through commercial supply



OUR SCIENCE & DEVELOPMENT PROGRAMS**

UniFlu (Universal influenza vaccine)	NA	PHASE 1	INFECTIOUS DISEASE
WEVEE VLP (Western, Eastern and Venezuelan equine encephalitic VLP)	NA	PHASE 1	INFECTIOUS DISEASE
EBS-Lassa (rVSV-vectored vaccine for Lassa fever)3	CEPI	PHASE 1	INFECTIOUS DISEASE
EBS-Marburg (rVSV-vectored vaccine for Marburg virus disease) 3	NIAID/AURO VACCINES	PRECLINICAL	INFECTIOUS DISEASE
EBS-Sudan (rVSV-vectored vaccine for Sudan virus disease) 3	NIAID/AURO VACCINES	PRECLINICAL	INFECTIOUS DISEASE
Pan-Ebola mAb (Ebola/Sudan monoclonal)	IBT	PRECLINICAL	INFECTIOUS DISEASE
CGRD-001 (Pralidoxime chloride/atropine auto-injector)	DoD	DEVELOPMENT	NERVE AGENT ANTIDOTE
EGRD-001 (Diazepam auto-injector)	DoD	DEVELOPMENT	NERVE AGENT ANTIDOTE
SIAN (Stabilized isomyl nitrite)	BARDA/SwRI	PHASE 1	CHEMICAL AGENT ANTIDOTE

CORPORATE HEADQUARTERS

- Gaithersburg, Maryland

CORPORATE AFFAIRS

- Washington, DC

DEVELOPMENT SERVICES

- Gaithersburg, Maryland

SCIENCE & DEVELOPMENT

- Dublin, Ireland
- Gaithersburg, Maryland
- Winnipeg, Canada

MANUFACTURING

- Baltimore, Maryland (Bayview)
- Baltimore, Maryland (Camden)
- Canton, Massachusetts
- Hattiesburg, Mississippi
- Lansing, Michigan
- Rockville, Maryland
- Winnipeg, Canada

SALES & MARKETING

- Bruchsal, Germany
- Gaithersburg, Maryland
- London, UK
- Philadelphia, Pennsylvania
- Redwood City, California
- Toronto, Canada

CONTACT INFORMATION

Corporate Headquarters
400 Professional Drive, Suite 400
Gaithersburg, MD 20879 USA
240.631.3200

Investor Inquiries
Richard Lindahl
EVP and Chief Financial Officer
240.631.3360
lindahlr@ebsi.com

Bioservices Inquiries
Brooke Marshall
Director, Sales & BD
800.441.4225
cdmo@ebsi.com

Media Inquiries
Assal Hellmer
Vice President, Communications
610-955-9928
mediarelations@ebsi.com

* Products approved by U.S. FDA. Approvals vary by country.

** These product candidates have not been approved by the U.S. FDA or any other regulatory authority.

1 Trobaird is not approved by the FDA and is procured by authorized government agencies under special circumstances

2 Status reflects both clinical and nonclinical development under the FDA Animal Efficacy Rule.

3 rVSV – recombinant Vesicular Stomatitis Virus

BARDA - Biomedical Advanced Research and Development Authority
CEPI - Coalition for Epidemic Preparedness Innovations
DoD - U.S. Department of Defense
IBT - Integrated BioTherapeutics
NIAID - National Institute of Allergy and Infectious Diseases
SwRI - Southwest Research Institute
USAMMDA - U.S. Army Medical Materiel Development Activity

EMERGENT®

Learn more at

emergentbiosolutions.com



Emergent BioSolutions®, ACAM2000®, Anthrasil®, BAT®, BioThrax®, Cyfendust™, RSDL®, NARCAN®, CNJ-016®, Trobaird®, TEMBEXA® and any and all Emergent BioSolutions Inc. brand, product, service and feature names, logos and slogans are trademarks or registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the United States or other countries. Ebanga™ is a trademark of Ridgeback Biotherapeutics LP. All rights reserved.
01/30/2023 PP-CORP-ALL-00001



Safe Harbor Statement

This document includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, our future goals and growth strategy, total contract value, the timing and results of clinical trials, development-stage programs and regulatory approvals, the intended results of our platforms and technologies, the timing of future deliverables, expansion into new global markets, and any other statements containing the words "will," "believes," "expects," "anticipates," "intends" "plans," "targets," "forecasts," "estimates" and similar expressions. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of publication, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information. There are a number of important factors that could cause the Company's actual results to differ materially from those indicated by such forward-looking statements. Investors should consider this cautionary language as well as the information identified under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our periodic reports filed with the Securities and Exchange Commission when evaluating our forward-looking statements.